BioSpace News Archive

Medical device and technology company Lazurite Holdings LLC (formerly Indago), today announced its collaboration with The Center for Health Affairs, the leading advocate for Northeast Ohio hospitals, and its business affiliate CHAMPS Healthcare, to bring revolutionary smart surgical tools to market and to operating rooms across Northeast Ohio and the United States.

Sigilon Therapeutics, Inc. today reported that the U.S. Food and Drug Administration (FDA) has notified the Company that its Phase 1/2 study of SIG-001 in patients with severe or moderately severe hemophilia A, has been placed on clinical hold.

bluebird bio, Inc . (Nasdaq: BLUE) today announced that the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded based on the review of all available data that the benefit-risk balance of medicinal products containing ZYNTEGLO™ (betibeglogene autotemcel gene therapy) remains favorable.

Kaneka Corporation received U.S.-FDA*1approval in April 2020 for its new brain aneurysm Embolization Coil*2,and has been marketing it through Kaneka Medical America LLC*3 since September 2020.

PureTech Health plc, a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vor Biopharma, announced the formation of a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

SAB Biotherapeutics announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will present at the Ladenburg Thalmann Annual Healthcare Conference on Tuesday, July 13 at 5:00 p.m. ET.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.

Salarius Pharmaceuticals, Inc. announced today that David Arthur, Chief Executive Officer, will present virtually at the 2021 Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021, at 3 p.m., ET.

Molecular Templates, Inc. today announced the dosing of the first subject in a Phase 1 study investigating MT-6402 in patients with PD-L1-positive solid tumors.

NeoDynamics AB, a MedTech company dedicated to advancing diagnosis and care of breast cancer, announced that the company has received the first German commercial order of its pulse biopsy system NeoNavia from Hermann-Josef-Hospital in Erkelenz, a teaching hospital of the University of Aachen, a reputed and certified breast centre.